Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors

Melanie J Davies, Vanita R Aroda, Mandeep Bajaj, Nuha A ElSayed, Francesco Giorgino, Jennifer Green, Rita R Kalyani, Nisa M Maruthur, Chantal Mathieu, Sylvia E Rosas, Peter Rossing, Tommy Slater, Tsvetalina Tankova, Pinar Topsever, Apostolos Tsapas, John B Buse

Published in

Diabetologia. Oct 02, 2026. Epub Oct 02, 2026.

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the consensus statement on the management of type 2 diabetes in non-pregnant adults, published since 2006 and last updated In 2022. The target audience is the multidisciplinary healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2022 informed new recommendations. This update has broadened the focus from the management of hyperglycaemia to the holistic management of type 2 diabetes and its risk of associated multiple long-term conditions. Fundamental aspects of diabetes care include promoting healthy lifestyle behaviours (healthy eating, 24 h physical behaviours including sleep, and avoiding tobacco and substance use), alongside the provision of psychological support and weight management interventions. For the management of people living with type 2 diabetes, earlier use, potentially from diagnosis, of sodium-glucose cotransporter 2 (SGLT2) inhibitors or/and glucagon-like peptide-1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated. Furthermore, earlier combination use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant CVD, chronic kidney disease and heart failure. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp through the consistent, equitable and systematic implementation of strategies and therapies that are already available.

PMID:
42825923
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.